1887

Abstract

Lactoferrin has been suggested to have antiviral activity against hepatitis C virus (HCV). The objective of this study was to compare the effects of recombinant camel lactoferrin (rcLf), native camel lactoferrin (ncLf) and their N and C fragments on HCV infection in Huh7.5 cells. ncLf was purified from camel milk and N and C lobes were generated proteolytically. rcLf and its fragments were synthesized using a Bac-to-Bac baculovirus expression system. All proteins except the C lobe of rcLf were soluble. The inhibitory effects on HCV entry into Huh7.5 cells were evaluated by incubation of HCV with Lf prior to infection or pre-treatment of the cells with Lf prior to infection. The inhibitory effect on HCV amplification in Huh7.5 cells was determined by Lf treatment of HCV-infected cells. Nested RT-PCR was performed to amplify intracellular HCV 5′ non-coding RNA sequences. rcLf and ncLf and their fragments could prevent HCV entry into Huh7.5 cells by direct interaction with the virus and inhibited virus amplification in Huh7.5 cells. Therefore, the N and C lobes of ncLf are sufficient to elicit anti-HCV effects in Huh7.5 cells. rcLf and its N lobe displayed similar HCV inhibitory effects to their native counterparts and may constitute an efficient and cost-effective approach for potential clinical applications.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.033894-0
2012-03-01
2019-10-14
Loading full text...

Full text loading...

/deliver/fulltext/jmm/61/3/375.html?itemId=/content/journal/jmm/10.1099/jmm.0.033894-0&mimeType=html&fmt=ahah

References

  1. Abe K. , Nozaki A. , Tamura K. , Ikeda M. , Naka K. , Dansako H. , Hoshino H. O. , Tanaka K. , Kato N. . ( 2007; ). Tandem repeats of lactoferrin-derived anti-hepatitis C virus peptide enhance antiviral activity in cultured human hepatocytes. . Microbiol Immunol 51:, 117–125.[PubMed] [CrossRef]
    [Google Scholar]
  2. Al-Majali A. M. , Ismail Z. B. , Al-Hami Y. , Nour A. Y. . ( 2007; ). Lactoferrin concentration in milk from camels (Camelus dromedarius) with and without subclinical mastitis. . Intern J Appl Res Vet Med 5:, 120–124.
    [Google Scholar]
  3. Alter M. J. . ( 2007; ). Epidemiology of hepatitis C virus infection. . World J Gastroenterol 13:, 2436–2441.[PubMed] [CrossRef]
    [Google Scholar]
  4. Azzam H. S. , Goertz C. , Fritts M. , Jonas W. B. . ( 2007; ). Natural products and chronic hepatitis C virus. . Liver Int 27:, 17–25. [CrossRef] [PubMed]
    [Google Scholar]
  5. Blight K. J. , McKeating J. A. , Rice C. M. . ( 2002; ). Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. . J Virol 76:, 13001–13014. [CrossRef] [PubMed]
    [Google Scholar]
  6. Bonkovsky H. L. . ( 2002; ). Iron as a comorbid factor in chronic viral hepatitis. . Am J Gastroenterol 97:, 1–4. [CrossRef] [PubMed]
    [Google Scholar]
  7. Chomczynski P. , Sacchi N. . ( 2006; ). The single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction: twenty-something years on. . Nat Protoc 1:, 581–585. [CrossRef] [PubMed]
    [Google Scholar]
  8. Conesa C. , Sánchez L. , Rota C. , Pérez M. D. , Calvo M. , Farnaud S. , Evans R. W. . ( 2008; ). Isolation of lactoferrin from milk of different species: calorimetric and antimicrobial studies. . Comp Biochem Physiol B Biochem Mol Biol 150:, 131–139. [CrossRef] [PubMed]
    [Google Scholar]
  9. el-Awady M. K. , Tabll A. A. , el-Abd Y. S. , Bahgat M. M. , Shoeb H. A. , Youssef S. S. , Bader el-Din N. G. , Redwan R. M. , el-Demellawy M. . & other authors ( 2006; ). HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro. . World J Gastroenterol 12:, 4836–4842.[PubMed]
    [Google Scholar]
  10. El-Fakharany E. M. , Tabll A. , Abd El-Wahab A. , Haroun B. M. , Redwan E. M. . ( 2008; ). Potential activity of camel milk-amylase and lactoferrin against hepatitis C virus infectivity in HepG2 and lymphocytes. . Hepat Mon 8:, 101–109.
    [Google Scholar]
  11. El-Fakharany E. M. , Haroun B. M. , Ng T. B. , Redwan E. R. . ( 2010; ). Oyster mushroom laccase inhibits hepatitis C virus entry into peripheral blood cells and hepatoma cells. . Protein Pept Lett 17:, 1031–1039. [CrossRef] [PubMed]
    [Google Scholar]
  12. El-Hatmi H. , Levieux A. , Levieux D. . ( 2006; ). Camel (Camelus dromedarius) immunoglobulin G, α-lactalbumin, serum albumin and lactoferrin in colostrum and milk during the early post partum period. . J Dairy Res 73:, 288–293. [CrossRef] [PubMed]
    [Google Scholar]
  13. Fried M. W. , Shiffman M. L. , Reddy K. R. , Smith C. , Marinos G. , Gonçales F. L. Jr , Häussinger D. , Diago M. , Carosi G. . & other authors ( 2002; ). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. . N Engl J Med 347:, 975–982. [CrossRef] [PubMed]
    [Google Scholar]
  14. Hirashima N. , Orito E. , Ohba K. , Kondo H. , Sakamoto T. , Matsunaga S. , Kato A. , Nukaya H. , Sakakibara K. . & other authors ( 2004; ). A randomized controlled trial of consensus interferon with or without lactoferrin for chronic hepatitis C patients with genotype 1b and high viral load. . Hepatol Res 29:, 9–12. [CrossRef] [PubMed]
    [Google Scholar]
  15. Ikeda M. , Sugiyama K. , Tanaka T. , Tanaka K. , Sekihara H. , Shimotohno K. , Kato N. . ( 1998; ). Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. . Biochem Biophys Res Commun 245:, 549–553. [CrossRef] [PubMed]
    [Google Scholar]
  16. Ikeda M. , Nozaki A. , Sugiyama K. , Tanaka T. , Naganuma A. , Tanaka K. , Sekihara H. , Shimotohno K. , Saito M. , Kato N. . ( 2000; ). Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. . Virus Res 66:, 51–63. [CrossRef] [PubMed]
    [Google Scholar]
  17. Ishibashi Y. , Takeda K. , Tsukidate N. , Miyazaki H. , Ohira K. , Dosaka-Akita H. , Nishimura M. . ( 2005; ). Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. . Hepatol Res 32:, 218–223. [CrossRef] [PubMed]
    [Google Scholar]
  18. Ishii K. , Takamura N. , Shinohara M. , Wakui N. , Shin H. , Sumino Y. , Ohmoto Y. , Teraguchi S. , Yamauchi K. . ( 2003; ). Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. . Hepatol Res 25:, 226–233. [CrossRef] [PubMed]
    [Google Scholar]
  19. Iwasa M. , Kaito M. , Ikoma J. , Takeo M. , Imoto I. , Adachi Y. , Yamauchi K. , Koizumi R. , Teraguchi S. . ( 2002; ). Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b. . Am J Gastroenterol 97:, 766–767. [CrossRef] [PubMed]
    [Google Scholar]
  20. Jaeckel E. , Cornberg M. , Wedemeyer H. , Santantonio T. , Mayer J. , Zankel M. , Pastore G. , Dietrich M. , Trautwein C. , Manns M. P. . German Acute Hepatitis C Therapy Group ( 2001; ). Treatment of acute hepatitis C with interferon alfa-2b. . N Engl J Med 345:, 1452–1457. [CrossRef] [PubMed]
    [Google Scholar]
  21. Kaito M. , Iwasa M. , Fujita N. , Kobayashi Y. , Kojima Y. , Ikoma J. , Imoto I. , Adachi Y. , Hamano H. , Yamauchi K. . ( 2007; ). Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin. . J Gastroenterol Hepatol 22:, 1894–1897. [CrossRef] [PubMed]
    [Google Scholar]
  22. Khan J. A. , Kumar P. , Paramasivam M. , Yadav R. S. , Sahani M. S. , Sharma S. , Srinivasan A. , Singh T. P. . ( 2001; ). Camel lactoferrin, a transferrin-cum-lactoferrin: crystal structure of camel apolactoferrin at 2.6 Å resolution and structural basis of its dual role. . J Mol Biol 309:, 751–761. [CrossRef] [PubMed]
    [Google Scholar]
  23. Konishi M. , Iwasa M. , Yamauchi K. , Sugimoto R. , Fujita N. , Kobayashi Y. , Watanabe S. , Teraguchi S. , Adachi Y. , Kaito M. . ( 2006; ). Lactoferrin inhibits lipid peroxidation in patients with chronic hepatitis C. . Hepatol Res 36:, 27–32. [CrossRef] [PubMed]
    [Google Scholar]
  24. Legrand D. , Pierce A. , Elass E. , Carpentier M. , Mariller C. , Mazurier J. . ( 2008; ). Lactoferrin structure and functions. . Adv Exp Med Biol 606:, 163–194. [CrossRef] [PubMed]
    [Google Scholar]
  25. Lönnerdal B. . ( 2009; ). Nutritional roles of lactoferrin. . Curr Opin Clin Nutr Metab Care 12:, 293–297. [CrossRef] [PubMed]
    [Google Scholar]
  26. Manns M. P. , McHutchison J. G. , Gordon S. C. , Rustgi V. K. , Shiffman M. , Reindollar R. , Goodman Z. D. , Koury K. , Ling M. , Albrecht J. K. . ( 2001; ). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. . Lancet 358:, 958–965. [CrossRef] [PubMed]
    [Google Scholar]
  27. Nozaki A. , Naganuma A. , Nakamura T. , Tanaka K. , Sekihara H. , Kato N. . ( 2000; ). A reliable internally controlled RT-nested PCR method for the detection of hepatitis C virus RNA. . Acta Med Okayama 54:, 253–257.[PubMed]
    [Google Scholar]
  28. Nozaki A. , Ikeda M. , Naganuma A. , Nakamura T. , Inudoh M. , Tanaka K. , Kato N. . ( 2003; ). Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. . J Biol Chem 278:, 10162–10173. [CrossRef] [PubMed]
    [Google Scholar]
  29. Ohno O. , Mizokami M. , Wu R. R. , Saleh M. G. , Ohba K. , Orito E. , Mukaide M. , Williams R. , Lau J. Y. . ( 1997; ). New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. . J Clin Microbiol 35:, 201–207.[PubMed]
    [Google Scholar]
  30. Redwan R. M. , Tabll A. . ( 2007; ). Camel lactoferrin markedly inhibits hepatitis C virus genotype 4 infection of human peripheral blood leukocytes. . J Immunoassay Immunochem 28:, 267–277. [CrossRef] [PubMed]
    [Google Scholar]
  31. Saleh D. A. , Shebl F. , Abdel-Hamid M. , Narooz S. , Mikhail N. , El-Batanony M. , El-Kafrawy S. , El-Daly M. , Sharaf S. . & other authors ( 2008; ). Incidence and risk factors for hepatitis C infection in a cohort of women in rural Egypt. . Trans R Soc Trop Med Hyg 102:, 921–928. [CrossRef] [PubMed]
    [Google Scholar]
  32. Sharma S. , Singh T. P. , Bhatia K. L. . ( 1999; ). Preparation and characterization of the N and C monoferric lobes of buffalo lactoferrin produced by proteolysis using proteinase K. . J Dairy Res 66:, 81–90. [CrossRef] [PubMed]
    [Google Scholar]
  33. Sy T. , Jamal M. M. . ( 2006; ). Epidemiology of hepatitis C virus (HCV) infection. . Int J Med Sci 3:, 41–46.[PubMed] [CrossRef]
    [Google Scholar]
  34. Tanaka K. , Ikeda M. , Nozaki A. , Kato N. , Tsuda H. , Saito S. , Sekihara H. . ( 1999; ). Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. . Jpn J Cancer Res 90:, 367–371. [CrossRef] [PubMed]
    [Google Scholar]
  35. Te H. S. , Jensen D. M. . ( 2010; ). Epidemiology of hepatitis B and C viruses: a global overview. . Clin Liver Dis 14:, 1–21, vii. [CrossRef] [PubMed]
    [Google Scholar]
  36. Ueno H. , Sato T. , Yamamoto S. , Tanaka K. , Ohkawa S. , Takagi H. , Yokosuka O. , Furuse J. , Saito H. . & other authors ( 2006; ). Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C. . Cancer Sci 97:, 1105–1110. [CrossRef] [PubMed]
    [Google Scholar]
  37. Yi M. , Kaneko S. , Yu D. Y. , Murakami S. . ( 1997; ). Hepatitis C virus envelope proteins bind lactoferrin. . J Virol 71:, 5997–6002.[PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.033894-0
Loading
/content/journal/jmm/10.1099/jmm.0.033894-0
Loading

Data & Media loading...

Supplementary methods 

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error